NEW YORK (AP) — Shares of Amgen Inc. rose Monday after a drug that competes with Amgen's anemia treatment Aranesp and Epogen was taken off the market because of severe allergic reactions and deaths in some patients.

THE SPARK: Affymax Inc. and Takeda Pharmaceutical Co. issued a recall of their anemia drug Omontys on Saturday, saying dialysis centers should stop using it. The companies said that around 50 patients have reported severe allergic reactions to Omontys and about five have died after their first dose of the drug.

Omontys is used to treat anemia in patients who have chronic kidney disease and are undergoing dialysis. Affymax and Takeda said about 25,000 patients have been treated with the drug.

THE BIG PICTURE: The Food and Drug Administration approved Omontys in late March. It is a once-per-month injection while older drugs have to be used once a week or more. Omontys, Aranesp, Epogen, and Johnson & Johnson's drug Procrit are all used to boost the formation of hemoglobin, a protein in red blood cells that delivers oxygen throughout the body. The drugs are used to reduce the need for blood transfusions.

Sales of the older anemia drugs have fallen sharply since 2007 because of a series of safety problems and restrictions on their use. Amgen said Aranesp sales fell 11 percent to $2.04 billion in 2012, and Epogen sales fell 5 percent to $1.94 billion.

THE ANALYSIS: UBS analyst Matthew Roden said it's not clear when Omontys will be back on the market or if sales will resume. Roden said sales of Epogen will improve while Omontys is off the market, and added that the recall might be good news for Amgen because the FDA might become more cautious about the safety of newer anemia drugs and generic versions of biotech drugs.

Roden kept a "Buy" rating on Amgen stock, with a price target of $98 per share.

SHARE ACTION: Amgen shares rose $3.47, or 4 percent, to $90.29 in afternoon trading. Shares of Affymax dropped $14.05, or 85.1 percent, to $2.47.


Publishing Services International Limited (PSIL) is the publisher and operator of a worldwide network of online news sites dedicated to delivering fair, accurate and relevant reporting from a variety of the world’s most trusted sources – from the biggest cities to the smallest towns.

We deliver positive and powerful messages to our readers, providing up‑to‑the‑second news that matters to the individual.

Our promise is to serve communities and individuals worldwide, delivering information that hasn’t always been available to them. We will give them back a voice – a voice that’s empowering because it is theirs – and provide a platform to communicate between themselves and the world.

We believe people are not just generic demographics; they are individuals with their own preferences and curiosities. We are about understanding these individuals, listening to them, and serving them.

We are the new pioneering spirit of news – we’re not talking to everyone, we’re talking with every one.

If you want your news, your voice, your way, on your time – we’ve got news for you.




If you have any questions or concerns please email us on


  • Australia, Toll Free 1-800-983-421
  • Hong Kong, Toll Free 800-906-187
  • Singapore, Toll Free 800-852-3871
  • USA/Canada, Toll Free 1-800-830-4132

Advertise With Us

Interested in being awesome?
Contact us by email or phone.